Treatment of parainfluenza 3 infection with DAS181 in a patient after allogeneic stem cell transplantation.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 21880586.
- Also identified by DOI 10.1093/cid/cir501.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Parainfluenza virus (PIV) can cause significant morbidity after allogeneic stem cell transplantation (SCT). We report the first use of inhaled DAS181 for PIV in an allogeneic SCT recipient. Symptoms, oxygenation, and pulmonary function tests improved. Nasopharyngeal samples showed a reduction in viral load. DAS181 should be systematically evaluated for severe PIV infection.
Medical subject headings
- Antiviral Agents
- Recombinant Fusion Proteins
- Respirovirus Infections
- Stem Cell Transplantation
- Transplantation, Homologous